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Abstract
Aging is associated with visceral adiposity, metabolic disorders, and chronic low-grade inflammation. 17α-estradiol (17α-E2), a naturally 
occurring enantiomer of 17β-estradiol (17β-E2), extends life span in male mice through unresolved mechanisms. We tested whether 17α-E2 
could alleviate age-related metabolic dysfunction and inflammation. 17α-E2 reduced body mass, visceral adiposity, and ectopic lipid deposition 
without decreasing lean mass. These declines were associated with reductions in energy intake due to the activation of hypothalamic anorexigenic 
pathways and direct effects of 17α-E2 on nutrient-sensing pathways in visceral adipose tissue. 17α-E2 did not alter energy expenditure or 
excretion. Fasting glucose, insulin, and glycosylated hemoglobin were also reduced by 17α-E2, and hyperinsulinemic-euglycemic clamps 
revealed improvements in peripheral glucose disposal and hepatic glucose production. Inflammatory mediators in visceral adipose tissue and the 
circulation were reduced by 17α-E2. 17α-E2 increased AMPKα and reduced mTOR complex 1 activity in visceral adipose tissue but not in liver 
or quadriceps muscle, which is in contrast to the generalized systemic effects of caloric restriction. These beneficial phenotypic changes occurred 
in the absence of feminization or cardiac dysfunction, two commonly observed deleterious effects of exogenous estrogen administration. Thus, 
17α-E2 holds potential as a novel therapeutic for alleviating age-related metabolic dysfunction through tissue-specific effects.
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Human life expectancy has increased dramatically in developed 
countries in the past several decades, and no deceleration of this 
trend appears imminent (1). Healthspan extension has failed to keep 
pace with increasing life expectancy, thus the incidence of chronic 
diseases and multimorbidity has become more common in the older 
adult population (2,3). Physiological aging and age-related diseases 
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can be delayed by interventions that modulate nutrient-sensing path-
ways (4,5). The most consistent and effective intervention among 
mammals is calorie restriction (CR) without malnutrition (6). CR 
protects against a number of age-related diseases through mecha-
nisms that are not fully understood, although improvements in 
regional adiposity, ectopic lipid deposition, metabolic homeostasis, 
and inflammatory status likely play a role (6–9).
White adipose tissue (WAT) influences physiological aging and 
disease onset by modulating macronutrient homeostasis and sys-
temic inflammation (10). Advancing age is associated with WAT 
insulin resistance and pro-inflammatory activity, which in turn con-
tribute to the expansion of visceral adiposity, ectopic lipid deposition, 
and metabolic dysfunction (11–14). Visceral adiposity and ectopic 
lipid accumulation are linked with morbidity and all-cause mortal-
ity in aged mammals (15,16). Despite evidence indicating that CR 
improves regional adiposity, metabolic parameters, and inflamma-
tory status in obese older adults (17–19), it remains unclear whether 
CR is feasible and/or appropriate in nonobese older adults (20,21). 
Moreover, dietary interventions that restrict calorie intake are often 
difficult to maintain (22). Given these limitations, attention has been 
directed toward selectively modulating nutrient-sensing and inflam-
matory pathways to enhance healthspan without modifying calorie 
intake. Pharmacological interventions may provide solutions to alle-
viate age-related dysfunction without the need for dietary restriction.
17α-estradiol (17α-E2) has emerged as a candidate compound 
for the extension of healthspan, as recent observations document an 
extension of life span in male mice fed a diet enriched with 17α-E2 
(23). 17α-E2 is a naturally occurring enantiomer of 17β-estradiol 
(17β-E2), yet appears to be nonfeminizing due to minimal activa-
tion of classical estrogen receptors, ERα and ERβ (24,25). The 
signaling mechanism(s) by which 17α-E2 elicits downstream effects 
remains elusive despite having been investigated for several decades. 
Although 17α-E2 is found in several mammalian tissues, urine, 
and plasma from both sexes (26,27), the physiological functions 
of endogenous 17α-E2 are unclear. It has been reported to serve 
a neuroprotective role due to being consistently found, and likely 
generated, in the brain (28,29). Supporting this premise are stud-
ies that report 17α-E2 protects against neuronal death in models 
of ischemia, Alzheimer’s, and Parkinson’s diseases (30–32), although 
this and other potential functions remain incompletely understood. 
In the present set of experiments, we tested whether late-life admin-
istration of 17α-E2 positively affects age-related perturbations in 
regional adiposity, metabolic homeostasis, and inflammatory status.
Materials and Methods
Control and Experimental Diets
TestDiet, a division of Purina Mills (Richmond, IN), prepared all the 
diets. Study 1 utilized LabDiet 5LG6 (65.4% CHO, 22.4% PRO, 
12.2% FAT) as the control (CON) diet and was supplemented with 
17α-E2 (14.4 ppm; Steraloids, Newport, RI) for the treatment diet. 
Study 2 utilized LabDiet 58YP (66.4% CHO, 20.5% PRO, 13.1% 
FAT) as the CON diet and was supplemented 17α-E2 (14.4 ppm) for 
the treatment diet.
Animals
All mice (male C57BL/6) used for these studies were obtained 
from the National Institute on Aging and were individually housed 
at 24 ± 0.5°C on a 12:12-hour light-dark cycle. Unless otherwise 
noted, mice had ad libitum access to food and water throughout 
the experimental timeframe. For Study 1, 18-month-old mice were 
randomized by body mass, body composition, and fasting glucose to 
CON or 17α-E2 treatment groups (n = 10/group). Body mass and 
composition were measured weekly throughout the 15-week inter-
vention. A second cohort of mice (n = 10/group) underwent iden-
tical treatment conditions at the Yale University Mouse Metabolic 
Phenotyping Center (MMPC) in preparation for hyperinsulinemic-
euglycemic clamp analyses following a 10-week intervention. For 
Study 2, 20-month-old mice were randomized by body mass, body 
composition, fasting glucose, and glycosylated hemoglobin (HbA1c) 
to CON, 17α-E2, or CR treatment groups. Body mass and food 
intake were measured daily, whereas body composition was meas-
ured weekly throughout the 5-week intervention. Daily food allot-
ment for the CR treatment group was calculated based upon body 
mass changes in the 17α-E2 treatment group from the previous day. 
This design allowed for weight-matching between the 17α-E2 and 
CR treatment groups and averaged out to an 18% restriction over 
the course of the study. The CR mice received half of their daily food 
allotment at 6 AM and the remainder at 6 PM . Body composition 
was assessed by quantitative magnetic resonance using an EchoMRI-
100H analyzer (Houston, TX) (33). Regional adiposity was assessed 
by microcomputed tomography (microCT) scanning and reconstruc-
tion using a Scanco VivaCT 40 (Wayne, PA) (34). Body tempera-
tures were measured twice daily (~6 AM and 6 PM) during Study 
2 using a Thermalert TH-8 (Physitemp, Clifton, NJ) rodent rectal 
thermometer. At the conclusion of each study, mice were anesthe-
tized with isoflurane and euthanized by cervical dislocation prior 
to dissection. Blood was collected into EDTA-lined tubes by cardiac 
puncture, and plasma was collected and frozen. Tissues were excised, 
weighed, flash frozen, and stored at −80°C unless otherwise noted. 
Small sections of liver and pancreas were fixed in 4% paraformal-
dehyde in preparation for paraffin embedding and future analyses. 
Small sections of eWAT and iWAT were washed and fixed in prepa-
ration for assessing SA-βgal+. All animal procedures were reviewed 
and approved by the Institutional Animal Care and Use Committees 
at Mayo Clinic or Yale University.
Plasma Analytes
Plasma adipokines, cytokines, and chemokines were evaluated using 
Multiplexing LASER Bead Technology (Eve Technologies, Calgary, 
AB). Plasma testosterone, 17β-E2, and 17α-E2 were evaluated by 
LC/MS/MS (29).
Real-time PCR
Total RNA was extracted from WAT, liver, and quadriceps using Trizol 
(Life Technologies, Carlsbad, CA) and was reverse transcribed to 
cDNA with the M-MLV Reverse Transcriptase kit (Life Technologies). 
Real-time PCR was performed in a 7500 Fast Real Time PCR System 
(Applied Biosystems, Foster City, CA) using TaqMan Fast Universal 
PCR Master Mix (Life Technologies) and predesigned primers 
and probes from Applied Biosystems. Target gene expression was 
expressed as 2−ΔΔCT by the comparative CT method (35) and normal-
ized to the expression of TATA-binding protein. Hypothalamic RNA 
was extracted and processed as previously described (36).
Senescence-associated β-Galactosidase
Cellular SA-βgal+ was assessed as previously described (37).
Ectopic Lipid Analyses
Paraffin-embedded liver sections were qualitatively evaluated for 
lipid accumulation by staining with osmium tetroxide (38). Liver 












and quadriceps triglyceride concentrations were evaluated follow-
ing the extraction of total lipid as previously described (39). Final 
triglyceride concentrations were then measured using a spectropho-
tometric assay (Sigma-Aldrich).
In Vivo Metabolic Analyses
Unless otherwise noted, all experiments requiring fasting conditions 
were performed in the afternoon following the removal of food 
in the morning (~8 AM). To ensure fasting conditions, mice were 
transferred to clean cages with sawdust bedding. Fasting (6 hours) 
glucose was evaluated using a OneTouch Ultra Blood Glucose 
Monitoring System (Johnson & Johnson, New Brunswick, NJ). 
Fasting (6 hours) insulin was evaluated using a Mouse Ultrasensitive 
Insulin ELISA from Alpco (Salem, NH). HbA1c was assessed by 
A1C-Now Monitoring kits (Bayer, Whippany, NJ). Glucose toler-
ance tests were performed following a 6-hour fast at a dose of 1.0 g/
kg body mass. Blood glucose was measured as described earlier at 
the time of injection (time 0) and at 15, 30, 60, 90, and 120 min-
utes post injection. Hyperinsulinemic-euglycemic clamp analyses 
and follow-up procedures were performed by the Yale University 
MMPC as previously described (40). Indirect calorimetry and vol-
untary activity were measured using the Oxymax System from 
Columbus Instruments (Columbus, OH). Due to differences in body 
mass between groups, all indirect calorimetry data were normalized 
to lean mass (LBM).
Western Blotting
WAT, liver, and quadriceps were homogenized in Cell Lysis Buffer 
(Cell Signaling, Danvers, MA) with protease inhibitors (Sigma-
Aldrich). Total protein was quantified using BCA Protein Assay 
Reagent Kit (Pierce, Rockford, IL). Proteins were separated on 
4%–15% gradient SDS-PAGE gels and transferred to immuno-blot 
PVDF membranes (Bio-Rad, Hercules, CA). All primary antibod-
ies were purchased from Cell Signaling and were used according 
to manufacturer’s suggestions. HRP-linked secondary antibodies 
(Santa Cruz, Santa Cruz, CA) were detected using an ECL Western 
Blotting Substrate Kit (Pierce).
Fecal Energy Excretion
Feces were collected and analyzed by bomb calorimetry as previ-
ously described (41).
Pancreatic Insulin Immunohistochemistry
Sections of paraffin-embedded pancreas were mounted on glass 
slides and processed for insulin as previously described (42). 
Immunoreactivity was visualized with 3,3-diaminobenzidine and 
counter-stained with hematoxylin. Insulin primary antibody was 
purchased from Dako (Carpinteria, CA). Biotinylated secondary 
antibody was purchased from Vector Laboratories (Burlingame, 
CA). HRP-conjugated biotin tertiary antibody was purchased from 
Vector Laboratories. Completed slides were scanned, and total pan-
creatic and insulin area were quantified with Image J.
Hepatic DNA Damage
Sections of paraffin-embedded liver were mounted on glass slides 
and processed for γH2A.X staining on telomere regions as previ-
ously described (43). γH2A.X antibody was purchased from Cell 
Signaling. Biotinylated secondary antibody and Fluorescein Avidin 
DCS were purchased from Vector Laboratories. Following γH2A.X 
immunofluorescence, telomere immunoFISH was performed using 
Cy-3–labeled telomere-specific (CCCTAA) peptide nucleic acid 
probe (Panagene, Daejeon, KR). Counter-staining was done with 
DAPI and images were taken and in-depth Z stacking was used (a 
minimum of 40 optical slices with ×63 objective).
U2OS Cell Transfection and Estrogen Receptor 
Activation
U2OS osteosarcoma cells were cultured in phenol-free αMEM 
with 10% FBS (Hyclone, Logan, UT) and 1% antibiotic/antimy-
cotic (Life Technologies). Cells were plated (2.6 × 104 cells/cm2) in 
12-well plates the day before transfection. Cells were co-transfected 
with 500 ng of an ERα or ERβ expression construct and 500 ng of 
an estrogen response element-luciferase reporter plasmid (44) using 
FuGene6 transfection reagent (Promega, Madison, WI). The follow-
ing day, cells were treated with increasing concentrations of 17α-E2 
and 17β-E2 in charcoal-stripped FBS-containing media. Cells were 
harvested 24 hours later and assayed for luciferase activity as previ-
ously described (45).
3T3-L1 Differentiation and AMPKα Activation
3T3-L1 cells were obtained from ATCC (Manassas, VA) and grown 
and differentiated according to vendor instructions. Following 
10 days of differentiation, when more than 70% of cells had vis-
ible lipid droplets, we treated for 2 hours with vehicle (EtOH), 17α-
E2 (10 nM and 100 nM; Steraloids), 17β-E2 (10 nM and 100 nM; 
Steraloids), or A-769662 (A76; 100  μM; Tocris, Minneapolis, 
MN). Cells were harvested and analyzed for AMPKα activation as 
described in the Western blotting section.
Cardiac Function
High-resolution ultrasound imaging was used to evaluate ventricu-
lar function and mass. Short- and long-axis views were assessed as 
previously described (46).
Physical Function Analyses
Forelimb grip strength and maximal treadmill endurance were eval-
uated as previously described (47).
Statistical Analyses
Analyses of differences between groups were performed by Student’s 
t test, one-way analysis of variance, or repeated-measures analysis of 
variance where appropriate using GraphPad Prism Software, version 
6.0. Values are presented as mean ± SEM with p values less than .05 
considered to be significant.
Results
17α-E2 Reduces Body Mass and Adiposity
Aging is associated with increased visceral adiposity related to 
declines in subcutaneous WAT functional capacity (48). We tested 
how 17α-E2 administration affects body mass and composition in 
aged male mice. Two independent studies revealed that 17α-E2 pre-
vents gains (Figure 1A and B; Study 1) or elicits reductions (Figure 1K 
and L; Study 2) in body mass and adiposity. Study 2 utilized a pair-
feeding strategy that effectively demonstrated that 17α-E2 has direct 
and more robust effects on the diminishment of adiposity than 
mild CR treatment (18%). The reduction in whole-body adiposity 
was primarily due to declines in visceral adiposity (Figure 1D and 












F). Intraperitoneal WAT depots (epididymal [eWAT] and mesen-
teric [mWAT]) were diminished more than extraperitoneal depots 
(inguinal [iWAT], subscapular [scWAT], and perirenal [pWAT]) 
(Supplementary Figure 1A and B). Circulating adiponectin and leptin 
were decreased following 17α-E2 administration (Figure 1G and I). 
The reduction in leptin was anticipated because it serves as a surro-
gate marker of whole-body adiposity (49), which was confirmed by 
normalizing leptin to total adiposity (Figure 1H). The reduction in 
Figure 1. 17α-E2 reduces body mass and adiposity. Weekly changes in (A) total body mass, (B) fat mass, and (C) lean mass in CON (blue) and 17α-E2 (red) 
treatment groups from Study 1. Representative cross-sectional images of visceral (pink) and subcutaneous (gray) adiposity in the lumbar region of (D) CON and 
(E) 17α-E2 treatment groups at Week 12 of Study 1. (F) Quantitative analysis of regional adiposity in the lumbar region from CON and 17α-E2 treatment groups 
from Study 1. (G) Plasma leptin and (H) plasma leptin normalized to total, lean, and fat mass from CON and 17α-E2 treatment groups from Study 1. (I) Plasma 
adiponectin and (J) plasma adiponectin normalized to total, lean, and fat mass from CON and 17α-E2 treatment groups from Study 1. Daily changes in (K) total 
body mass and weekly changes in (L) lean:fat mass ratios in CON (yellow), 17α-E2 (orange), and calorie restriction (green) treatment groups from Study 2. All 
data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by repeated measures analysis of variance (A–C, K, L) or Student’s t 
test (F–J). *p < .05. #p < .01. $p < .005.












adiponectin was unexpected because it is often inversely correlated 
with visceral adiposity (49). However, expressing adiponectin levels 
relative to total adiposity revealed an increase in adiponectin per unit 
of fat mass (Figure 1J). 17α-E2 did not reduce lean mass (Figure 1C) 
and was associated with greater preservation of lean:fat mass ratios 
than mild CR treatment (18%; Figure  1L). With the exclusion of 
WAT depots, all other organ masses including liver, quadriceps, kid-
neys, heart, spleen, and brown adipose tissue were nearly identical 
between treatment groups (Supplementary Figure 1A and B).
17α-E2 Reduces Energy Intake but not Expenditure 
or Excretion
An imbalance between energy intake and expenditure can contrib-
ute to lipid redistribution and metabolic dysfunction (5). Because 
17α-E2 reduced body mass and adiposity (Figure  1), we evaluated 
factors involved in determining body size and composition. Chronic 
administration of 17α-E2 did not alter oxygen consumption, energy 
expenditure, or voluntary activity in Studies 1 or 2 (Figure 2A–F), nor 
did we find changes in fecal energy excretion in Study 2 (Figure 2G). 
17α-E2 did not alter body temperatures during dark or light phases 
(Supplementary Figure  2A and B). These findings suggest that the 
decline in body mass and adiposity may not be related to altered meta-
bolic rate but may result from changes in energy intake. Consistent 
with this, Study 2 revealed that 17α-E2 reduced total calorie consump-
tion (Figure 2I). Calorie intake normalized to mass was also reduced 
(Figure  2J), particularly within the first 2 weeks of treatment when 
changes in body mass and adiposity were most evident. Thereafter, 
calorie intake was similar to levels observed in CON mice, suggesting 
that 17α-E2 may alter calorie intake to maintain a lower body mass. 
This speculation was supported by the observation that the CR group 
required continually diminished allotments of food to remain weight-
matched with 17α-E2–treated mice (Figure 2I and J). Assessment of 
hypothalamic transcripts revealed increased expression of anorexi-
genic mediators including the leptin receptor (LEPR), pro-opiomelano-
cortin (POMC), and the downstream mediator of POMC actions, 
the melanocortin-4 receptor (MC4R) following 17α-E2 treatment 
Figure 2. 17α-E2 reduces energy intake but not expenditure or excretion. (A) Oxygen consumption, (B) energy expenditure, and (C) voluntary activity during 
Weeks 0 and 12 from CON (blue) and 17α-E2 (red) treatment groups from Study 1. (D) Oxygen consumption, (E) energy expenditure, and (F) voluntary activity 
during Week 4 from CON (yellow), 17α-E2 (orange), and calorie restriction (CR; green) treatment groups from Study 2. (G) Fecal energy excretion during Weeks 
0 and 5 from CON, 17α-E2, and CR treatment groups from Study 2. (I) Daily calorie intake per week and total calories consumed from CON, 17α-E2, and CR 
treatment groups from Study 2. (J) Daily calorie intake per week normalized to body mass and total calories consumed normalized to body mass from CON, 
17α-E2, and CR treatment groups from Study 2. (K) Anorexigenic gene expression in the hypothalamus from CON, 17α-E2, and CR treatment groups from Study 
2. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by Student’s t test (A–C) or one-way analysis of variance (D–K). 
♦p < .05 (different from nonlabeled groups).












(Figure  2K). Elevated anorexigenic gene expression was associated 
with increased ERα transcription, which is believed to be the primary 
mechanism by which 17β-E2 signals in the hypothalamus to regulate 
feeding behavior (50). Collectively, these observations suggest that one 
of the mechanisms through which 17α-E2 may decrease body mass 
and adiposity is by acting as a satiety factor. However, additional evi-
dence suggests that declines in caloric intake do not solely account for 
changes in adiposity and metabolic parameters by 17α-E2.
17α-E2 Reduces Inflammation in WAT and the 
Circulation
Chronic low-grade inflammation is linked with age-related metabolic 
dysfunction (51). WATs, particularly visceral depots, are a source of 
circulating pro-inflammatory mediators (52,53). Reports suggest that 
accumulation of senescent cells within WAT may contribute to this 
pro-inflammatory phenotype (37,54,55). Because 17α-E2 reduced adi-
posity, we determined whether these improvements were accompanied 
by a dampening of WAT pro-inflammatory mediators and senescent 
cell burden. 17α-E2 reduced expression of several pro-inflammatory 
transcripts in visceral (eWAT), but not subcutaneous (iWAT), WAT 
(Figure 3A and B). These transcripts included tumor necrosis factor-α 
(TNFα), monocyte chemotactic protein-1 (MCP1), interleukin (IL)-
6, IL1α, IL1β, and EGF-like module-containing mucin-like hormone 
receptor-like 1 (F4/80), a macrophage marker (56). Although several 
of these cytokines and chemokines have been associated with the 
senescence-associated secretory phenotype (57), we did not observe 
significant differences in senescence-related markers, including senes-
cence-associated β-galactosidase positivity (SA-βgal+), p16, p21, or 
plasminogen activator inhibitor-1 (PAI-1) transcripts in visceral or 
subcutaneous WAT (Figure 3C–J). However, the reduction in visceral 
Figure 3. 17α-E2 reduces inflammation in white adipose tissue (WAT) and the circulation. Pro-inflammatory gene expression in (A) subcutaneous (iWAT) and 
(B) visceral (eWAT) WAT from CON (blue) and 17α-E2 (red) treatment groups from Study 1. Representative images of SA-βgal+ in iWAT from (C) CON and (D) 
17α-E2 treatment groups from Study 1. (E) Percent SA-βgal+ in iWAT from CON and 17α-E2 treatment groups from Study 1. (F) SA-mRNA expression in iWAT 
from CON and 17α-E2 treatment groups from Study 1. Representative images of SA-βgal+ in eWAT from (G) CON and (H) 17α-E2 treatment groups from Study 
1. (I) Percent SA-βgal+ in eWAT from CON and 17α-E2 treatment groups from Study 1. (J) SA-mRNA expression in eWAT from CON and 17α-E2 treatment groups 
from Study 1. (K) Plasma pro-inflammatory cytokines and chemokines in CON and 17α-E2 treatment groups at Week 15 of Study 1. Arrows indicate SA-βgal+ 
activity in representative samples. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test. *p < .05. #p 
< .01. $p < .005. Scale bars: 50 µm.












WAT pro-inflammatory activity was associated with declines in circu-
lating pro-inflammatory analytes. Many of the inflammatory markers 
suppressed in visceral WAT by 17α-E2 were also reduced in the circu-
lation, with several additional cytokines and chemokines also trending 
downwards (Figure 3K). Collectively, these findings indicate an overall 
improvement in systemic inflammatory status.
17α-E2 Reverses Age-related Lipid Redistribution 
and Restores Metabolic Flexibility
Metabolic dysfunction in older adults is associated with ectopic 
lipid deposition, glucose intolerance, and insulin resistance (11–13). 
Age-related changes in regional adiposity and systemic inflamma-
tion are predictors of metabolic decline (10,48). Given that 17α-
E2 reduced adiposity and inflammatory status (Figures 1 and 3), 
we tested whether 17α-E2 improved metabolic health. Consistent 
with reduced visceral adiposity (Figure 1), 17α-E2 suppressed lipid 
accumulation in liver and quadriceps (Figure  4A–D). This was 
accompanied by improvements in glucose homeostasis, as indi-
cated by declines in fasting glucose, fasting insulin, and HbA1c, 
coupled with enhanced glucose tolerance (Figure  4E–I). Studies 
utilizing hyperinsulinemic-euglycemic clamps revealed that 17α-E2 
restored whole-body insulin sensitivity (Figure  5A–D). Improved 
whole-body insulin sensitivity was accounted for by increased rates 
of insulin-stimulated glucose disposal and reduced rates of hepatic 
glucose production (Figure 5E and F). Furthermore, tissue-specific 
rates of insulin-stimulated glucose transport were increased in 
quadriceps, heart, and visceral (eWAT) WAT (Figure 5H). Clamps 
further revealed that 17α-E2 enhanced metabolic plasticity in liver 
and WAT in that the suppression of hepatic glucose production 
and lipolysis under insulin-stimulated conditions were improved 
(Figure 5G and J). 17α-E2 treatment also reduced pancreatic β-cell 
area (Supplementary Figure 3A–D), suggesting that improvements 
in glucose homeostasis reduced pancreatic β-cell demand. This is 
commonly observed in mammals with improved peripheral insulin 
sensitivity due to reversal of hyperinsulinemic compensation (58). 
Study 2 also indicated enhancements in glucose homeostasis by 
17α-E2 to an extent similar to that observed following mild CR 
treatment (Figure 4J and K). Given that hyperglycemia and hepatic 
lipid accumulation are associated with cellular senescence in the 
liver (59,60), we evaluated telomere-associated DNA damage, an 
indicator of senescence onset (43). Improvements in hepatic lipid 
deposition and metabolic homeostasis by 17α-E2 were associ-
ated with reduced hepatocyte DNA damage foci (Supplementary 
Figure  4A–D). We speculate that 17a-E2 treatment may improve 
Figure 4. 17α-E2 reverses age-related lipid redistribution and improves glucose homeostasis. Representative images of total hepatic lipid content from (A) CON 
and (B) 17α-E2 treatment groups from Study 1. Triglyceride accumulation in (C) liver and (D) quadriceps from CON (blue) and 17α-E2 (red) treatment groups 
from Study 1. (E) Fasting glucose at Weeks 0 and 15 in CON and 17α-E2 treatment groups from Study 1. (F) Fasting insulin and (G) Glycosylated hemoglobin 
(HbA1c) at Week 15 in CON and 17α-E2 treatment groups from Study 1. (H) Glucose tolerance at Week 10 in CON and 17α-E2 treatment groups from Study 1. (I) 
Glucose tolerance area under the curve at Week 10 in CON and 17α-E2 treatment groups from Study 1. (J) Fasting glucose at Weeks 0, 2, and 4 in CON (yellow), 
17α-E2 (orange), and calorie restriction (CR; green) treatment groups from Study 2. (K) HbA1c at Weeks 0 and 5 in CON, 17α-E2, and CR treatment groups from 
Study 2. All data are expressed as mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test (C–G), repeated measures analysis of 
variance (ANOVA; H), or one-way ANOVA (J–K). *p < .05. #p < .01. $p < .005. ♦p < .05 (different from nonlabeled groups); ♠p < .05 (different from nonlabeled and 
♦-labeled groups). Scale bars: 200 µm.












overall liver function by alleviating age-related lipid accumulation 
and impaired glucose homeostasis.
17α-E2 Selectively Modulates Nutrient-sensing 
Pathways
Dysregulation of nutrient-sensing pathways contributes to the aging 
process and onset of age-related diseases (4,5). Many dietary, phar-
macological, and genetic interventions that extend life span and delay 
or alleviate age-related dysfunction directly or indirectly modulate 
AMPKα and/or mTOR signaling (6). 17α-E2 increased AMPKα and 
reduced mTOR complex 1 activity (reduced p-S6) in visceral (eWAT) 
WAT (Figure 6A and D). We did not observe similar outcomes in 
liver (Figure 6B and E) or quadriceps (Figure 6C and F), which are 
known to respond to CR and exercise through AMPKα and mTOR 
modulation (5,6). Thus, unlike CR, 17α-E2 selectively modulates 
AMPKα and mTOR activity in a tissue-specific manner. Treatment 
of cultured 3T3-L1 adipocytes revealed that acute administration of 
17α-E2 activates AMPKα (Supplementary Figure  5A and B), sug-
gesting that 17α-E2 may have direct effects in WAT. Moreover, these 
effects appear greater than those observed following 17β-E2 treat-
ment (Supplementary Figure  5A and B). Collectively, our findings 
suggest that 17α-E2 may preferentially modulate nutrient-sensing 
pathways in WAT, which is in contrast to the global effects of CR.
17α-E2 Does not Feminize Male Mice
Several studies have shown that 17α-E2 has less binding affinity and 
activation potential of ERα and ERβ compared with 17β-E2 (24,25), 
and thus is unlikely to induce feminine characteristics (26,30,32). 
However, this has not been evaluated in long-term in vivo studies 
in which exogenous 17α-E2 was administered. We examined sev-
eral characteristics that would indicate whether chronic (15 weeks) 
17α-E2 administration feminizes male mice. 17α-E2 did not alter 
gonadal or seminiferous tubule mass, whereas breast mass was 
reduced (Figure 7A–C). No differences were found in circulating tes-
tosterone or 17β-E2 between treatment groups (Figure 7D and E). 
Differences would be expected if 17α-E2 were feminizing because 
oral estrogen therapies reduce bioavailable testosterone and increase 
17β-E2 in the circulation (61). As expected, circulating 17α-E2 was 
increased by exogenous administration (Figure 7F). Given that 17β-
E2 can modulate the expression of its own receptors (62), we evalu-
ated ERα and ERβ transcription in several tissues and found them 
to be unchanged by 17α-E2 (Figure 7G and H). This is in contrast to 
our findings in the hypothalamus (Figure 2K), suggesting that 17α-
E2 may modulate classical ER expression in a tissue-specific man-
ner. To confirm that 17α-E2 elicits less ERα and ERβ activity than 
17β-E2, we transfected U2OS cells with each receptor and exposed 
them to escalating doses of both hormones to evaluate reporter 
Figure 5. 17α-E2 improves systemic insulin sensitivity. (A) Glucose and (B) insulin under basal and clamped conditions from CON (blue) and 17α-E2 (red) 
treatment groups from Study 1. (C) Real-time and (D) average glucose infusion rates (GIRs) from CON and 17α-E2 treatment groups from Study 1. (E) Whole-body 
glucose disposal, (F) endogenous glucose production (EGP) under basal and clamped conditions, and (G) hyperinsulinemia-induced percent EGP suppression 
from CON and 17α-E2 treatment groups from Study 1. (H) Tissue-specific disposal of 2-deoxyglucose during hyperinsulinemia from CON and 17α-E2 treatment 
groups from Study 1. (I) Circulating free fatty acids (FFAs) under basal and clamped conditions and (J) percent lipolysis suppression during hyperinsulinemia 
from CON and 17α-E2 treatment groups from Study 1. All data are expressed as mean ± SEM of 7 mice per treatment group and were analyzed by Student’s t 
test (A, B, D–J) or repeated-measures analysis of variance (c). *p < .05. $p < .005.












gene activity. In agreement with a previous report (25), ER activa-
tion by 17α-E2 required ~20-fold higher concentrations to replicate 
reporter activity induced by 17β-E2 (Supplementary Figure 6A and 
B). Another potential deleterious effect associated with exogenous 
estrogen administration is cardiovascular disease progression due to 
chronic activation of classical ERs (63). We evaluated cardiac func-
tion (Supplementary Figure 7A–C) and physical function parameters 
(Figure 8A and B) in male mice chronically exposed to 17α-E2 and 
found no difference between treatment groups. Collectively, our 
observations suggest that 17α-E2 is nonfeminizing and does not 
impair cardiac or physical function parameters in male mice at the 
given dose and duration of treatment used here. Additional studies in 
female mice are needed to evaluate sex-specific responses to 17α-E2.
Discussion
17α-E2, a nonfeminizing enantiomer of 17β-E2, was recently found 
to extend life span in male mice through unknown mechanisms 
(23). 17β-E2 is reported to protect females from metabolic declines 
through central and peripheral actions (64,65). We hypothesized that 
17α-E2 may elicit similar effects in male mice and improve health-
span. We provide evidence that 17α-E2 alleviates metabolic and 
inflammatory dysfunction in old male mice by reducing calorie intake 
and beneficially altering nutrient-sensing and inflammatory pathways 
in visceral WAT. Our data indicate that 17α-E2 reduces visceral adi-
posity and chronic inflammation, both of which are associated with 
morbidity and mortality in older adults (16,66). We speculate that 
17α-E2 may be an attractive therapy to improve healthspan in older 
adults with metabolic and/or inflammatory dysfunction.
Age-related declines in WAT function promote lipid redistribu-
tion to favor ectopic deposition and visceral adiposity (11,67). These 
changes are linked with insulin resistance and the development of type 
2 diabetes (68,69). We found that 17α-E2 reduced overall body mass 
and adiposity, with declines in visceral fat, hepatic lipid, and muscle 
triglyceride. Our findings are in some ways like those seen in mam-
mals undergoing chronic CR (6,7). We anticipated that the reduction 
in body mass and adiposity by 17α-E2 might occur in response to 
altered metabolic balance to favor an energy deficit, as seen with CR. 
Assessment of oxygen consumption, activity, and body temperatures 
did not reveal evidence of increased energy expenditure in 17α-E2–
treated mice. We also considered decreased digestive efficiency as a 
potential contributing mechanism to reduced body mass and adiposity 
by 17α-E2. However, fecal energy content did not change in response 
to any treatment. Thus, in contrast to 17β-E2 (70), 17α-E2 does not 
appear to increase energy expenditure or alter nutrient bioavailability. 
Rather, our studies demonstrate reduced calorie intake in response to 
17α-E2 treatment, but this alone does not explain all of our findings, 
particularly why 17α-E2 selectively affects adipose tissue to a different 
extent than muscle or liver. The reduction in calorie intake was sus-
tained during the first 2 weeks of administration when body mass and 
adiposity were most robustly reduced. 17α-E2 altered calorie intake to 
maintain this lower body mass. These observations suggest that 17α-
E2 treatment improved body composition partially through reducing 
calorie intake, potentially to establish a new body mass set-point.
Feeding behavior is regulated in part by hypothalamic mecha-
nisms, whereby anorexigenic (POMC/CART-expressing) neuronal 
populations suppress calorie intake and metabolic output. These 
neuronal populations act largely in response to peripheral regula-
tors, including insulin and leptin (71). Leptin activation of POMC 
expressing neurons in response to a meal promotes the release of 
α-melanocyte-stimulating hormone (αMSH) (72). In turn, αMSH 
promotes satiety through selective binding to melanocortin-3 (MC3) 
and MC4 receptors, acting within the paraventricular and lateral 
nuclei of the hypothalamus (73). Assessment of hypothalamic expres-
sion of LEPR, POMC, and MC4R indicated an upregulation of these 
transcripts, and thus, the anorexigenic pathway, suggesting that 17α-
E2 might suppress calorie intake by improving leptin-mediated satiety 
effects. Aging is associated with progressive central leptin resistance 
Figure 6. 17α-E2 selectively activates AMPKα and suppresses mTOR complex 1. Representative Western blots of p-AMPKα, AMPKα, p-mTOR, mTOR, p-S6, S6, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from (A) visceral adipose (eWAT), (B) liver, and (C) quadriceps from CON and 17α-E2 treatment groups from 
Study 1. Densitometry results for p-AMPKα:AMPKα, p-mTOR:mTOR, and p-S6:S6 ratios from (D) visceral (eWAT), (E) liver, and (F) quadriceps from CON (blue) and 17α-
E2 (red) treatment groups from Study 1. All data are expressed as mean ± SEM of 7–10 mice per treatment group and were analyzed by Student’s t test (D–F). $p < .005.












(74). Resistance to leptin-mediated satiety signaling within the hypo-
thalamus may compound weight gain (75). Given the rise in LEPR 
mRNA expression in response to 17α-E2 treatment, we speculate 
that 17α-E2 may selectively improve hypothalamic leptin signaling 
to reduce calorie intake. Although the observed rise in LEPR mRNA 
expression supports this speculation, it is yet to be directly assessed.
In brain, 17β-E2 modulates calorie intake by acting primarily 
through ERα (50). ERα is abundantly expressed in POMC neurons (64), 
and deletion of ERα results in reduced hypothalamic POMC expres-
sion (76). Given the observed increase in hypothalamic ERα expres-
sion in 17α-E2–treated mice, selective activation of POMC-mediated 
satiety signaling may have been facilitated through enhanced hypotha-
lamic ERα signaling, and thus direct 17α-E2 effects. Deletion of ERα 
in POMC neurons results in hyperphagia without directly changing 
energy expenditure (50), suggesting that 17α-E2 may selectively modu-
late POMC-mediated calorie intake without altering energy expenditure. 
Combined observations from Studies 1 and 2 support this. We propose 
that 17α-E2 may at least partially reduce adiposity by promoting satiety.
In conjunction with declines in body mass and visceral adipos-
ity, 17α-E2 elicited significant improvements in several systemic 
variables associated with age-related morbidity. Pro-inflammatory 
mediators in visceral WAT and the circulation were reduced by 
17α-E2. Interestingly, subcutaneous WAT inflammatory markers 
remained unchanged. It remains unresolved whether 17α-E2 action 
is limited to visceral WAT, but this seems plausible given that previ-
ous studies show 17β-E2 has preferential effects on visceral WAT 
inflammatory processes (77,78). The activation of AMPKα and sup-
pression of mTOR activity by 17α-E2 in visceral WAT support this 
contention. Increased AMPKα and reduced mTOR activity blunt 
pro-inflammatory pathways by regulating nuclear factor kappa 
B (NFκB) activity (4,5). NFκB is the master regulator of several 
pro-inflammatory mediators commonly elevated with aging (79). 
Suppression of pro-inflammatory processes in visceral WAT is likely 
to improve systemic inflammatory status because visceral WAT is 
a major source of circulating cytokines and chemokines (52,53). 
Thus, the observed reduction in circulating pro-inflammatory ana-
lytes in response to 17α-E2 treatment may be related to improved 
visceral WAT inflammatory status. Despite declines in several pro-
inflammatory mediators, we did not find evidence of reduced cel-
lular senescence in WAT. Accumulation of senescent cells is believed 
to contribute to age-related chronic inflammation due to the pro-
inflammatory senescence-associated secretory phenotype (57,80). 
This is particularly true in WAT (37,54,55), which is susceptible to 
inflammation-mediated functional declines (10,48). 17α-E2 may 
suppress the senescence-associated secretory phenotype independent 
of changes of senescent cell accumulation, which has been shown 
Figure 7. 17α-E2 does not feminize male mice. (A) Gonadal, (B) seminiferous tubule, and (C) breast mass during necropsy from CON (blue) and 17α-E2 (red) 
treatment groups from Study 1. Plasma (D) testosterone, (E) 17β-E2, and (F) 17α-E2 in CON and 17α-E2 treatment groups at Week 15 of Study 1. (G) ERα and (H) 
ERβ mRNA expression in liver, quadriceps, subcutaneous and visceral WAT from CON and 17α-E2 treatment groups from Study 1. All data are expressed as 
mean ± SEM of 8–10 mice per treatment group and were analyzed by Student’s t test. *p < .05. $p < .005.












with metformin (81) and rapamycin (82). Alternatively, 17α-E2 
could suppress visceral WAT pro-inflammatory activity by reduc-
ing immune cell infiltration, which is increased with aging (83). 
The reduction in visceral WAT F4/80 expression supports this idea, 
although additional studies will be required to test this.
A decline in metabolic homeostasis is one of the more common 
morbidities associated with advancing age (11,84). The underly-
ing mechanisms are multifactorial, yet prevailing evidence suggests 
ectopic lipid deposition due to declines in WAT functional capacity 
and inflammatory status likely play a pivotal role (10,48). The accu-
mulation of lipid in liver and muscle has been shown to impair insu-
lin signaling and thereby promote hyperglycemia (14). Given that 
17α-E2 reduced visceral adiposity and pro-inflammatory mediators, 
we hypothesized lipid redistribution and macronutrient homeostasis 
would also be improved. Indeed, 17α-E2 reversed age-related ectopic 
lipid accumulation and enhanced glycemic control and insulin sen-
sitivity. These observations may be attributed to a combination of 
factors. First, WAT from 17α-E2–treated mice was more sensitive to 
insulin and thus exhibited greater insulin-mediated control of lipoly-
sis. This, coupled with reduced calorie intake, potentially contributed 
to declines in ectopic lipid accumulation in 17α-E2–treated mice. 
Perry and colleagues previously reported that WAT insulin resistance, 
and thus impaired suppression of lipolysis, promotes hepatic lipid 
accumulation and insulin resistance (85). 17α-E2 treatment enhanced 
liver and muscle insulin responsiveness, as evidenced by improved 
control of hepatic glucose production and peripheral glucose disposal, 
respectively. Although improved liver and muscle function occurs in 
response to reduced lipid accumulation (14,85), it remains unclear 
whether 17α-E2 directly mediates these effects. Another potential 
contributor to the observed enhancements in liver function is the 
reduction in hepatocyte DNA damage. Hepatic lipid accumulation 
and age-related liver diseases are linked with DNA damage and cellu-
lar senescence (60,86). Although 17α-E2 reduced telomere-associated 
DNA damage, which is unrepairable and a good predictor of senes-
cence onset (43), it remains unclear whether these results represent a 
potential mechanism that contributes to improvements in metabolic 
health, or serve as a surrogate marker of hepatic health.
A major caveat associated with exogenous administration of estro-
genic compounds is the potential for adverse biological consequences. 
Excess 17β-E2 activity can cause feminization (87) and increase car-
diovascular disease risk (88,89). Therefore, the challenge exists of how 
best to exploit the beneficial effects of 17β-E2 while circumventing 
the adverse biological consequences of exogenous administration. 
Studies in rodents and humans indicate that short-term administration 
of 17α-E2, the naturally occurring enantiomer of 17β-E2, does not 
induce deleterious effects (26,27). However, the emergence of deleteri-
ous effects following long-term 17α-E2 treatment is yet to be tested. 
We found that chronic 17α-E2 treatment did not impair cardiac func-
tion, exercise endurance, or muscular strength. Moreover, increased 
circulating 17α-E2 following oral administration was not associated 
with changes in sex organ mass or circulating testosterone or 17β-E2 
levels in our male mice. This is consistent with the possibility that 
the absence of feminization by 17α-E2 results from a lack of classical 
ER (ERα and ERβ) activation, which is supported by our transfection 
experiments and prior reports (24,25).
In summary, we provide evidence that 17α-E2 is a potential ther-
apeutic to improve healthspan through selective modulation of path-
ways that control calorie intake in the hypothalamus and nutrient 
sensing in visceral adipose tissue. Improvements in systemic health 
in 17α-E2–treated mice reflected a reduction in pro-inflammatory 
status, attributed predominantly to improvements in visceral WAT 
inflammation and metabolic regulation. The beneficial effects of 
17α-E2 appear to occur in the absence of deleterious effects on car-
diac function and feminization. 17α-E2 may prove to have clinical 
application for alleviating age-related chronic diseases.
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